Methods for treating renal cell carcinoma
AssigneeCorvus Pharmaceuticals, Inc.
InventorsRichard A. Miller, Lih-Yun Hsu
Life of this patent
Estimating the term…
Abstract
Provided herein, inter alia, are methods of treating renal cell carcinoma with an adenosine A2A receptor antagonist and a CTLA-4 inhibitor. The method may optionally further comprise administering a PD-1 inhibitor.
Claims21
1-24. (canceled)
A method for treating renal cell carcinoma in a patient in need thereof, the method comprising:
- (a) detecting:
- (i) an increased level of gene expression of a biomarker gene, relative to a control, in a biological sample obtained from the patient, wherein the biomarker gene is CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL8, IL-1β, PTGS2, or a combination of two or more thereof, or
- (ii) an increased level of myeloid suppressor cells relative to a control in a biological sample obtained from the patient;
- and
- (b) administering to the patient an effective amount of an adenosine A2A receptor and an effective amount of a CTLA-4 inhibitor.
A method for treating renal cell carcinoma in a patient in need thereof, the method comprising administering to the patient an effective amount of an adenosine A2A receptor antagonist and an effective amount of a CTLA-4 inhibitor;
- wherein a biological sample obtained from the patient has:
- (i) an increased level of gene expression relative to a control of a biomarker gene, wherein the biomarker gene is CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL8, IL-1β, PTGS2, or a combination of two or more thereof, or
- (ii) an increased level of myeloid suppressor cells relative to a control.
A method for treating renal cell carcinoma in a patient in need thereof, the method comprising administering to the patient an effective amount of an adenosine A2A receptor antagonist, an effective amount of a CTLA-4 inhibitor, and an effective amount of a PD-1 inhibitor, wherein:
- (a) the effective amount of the CTLA-4 inhibitor is a reduced effective amount;
- (b) the effective amount of the PD-1 inhibitor is a reduced effective amount;
- or (c) the effective amount of the CTLA-4 inhibitor is a reduced effective amount and the effective amount of the PD-1 inhibitor is a reduced effective amount.
Dependencies are inferred from the claim text.